Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer - PubMed (original) (raw)

Review

doi: 10.1038/nrd1381.

Affiliations

• PMID: 15136787
• DOI: 10.1038/nrd1381

Review

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Napoleone Ferrara et al. Nat Rev Drug Discov. 2004 May.

No abstract available

PubMed Disclaimer

Similar articles

• Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
  Los M, Roodhart JM, Voest EE. Los M, et al. Oncologist. 2007 Apr;12(4):443-50. doi: 10.1634/theoncologist.12-4-443. Oncologist. 2007. PMID: 17470687 Review.
• Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer.
  Díaz-Rubio E, Schmoll HJ. Díaz-Rubio E, et al. Oncology. 2005;69 Suppl 3:1-3. doi: 10.1159/000088477. Epub 2005 Nov 21. Oncology. 2005. PMID: 16301829 Review. No abstract available.
• [New medications; bevacizumab].
  Cohen AF, van Bronswijk H. Cohen AF, et al. Ned Tijdschr Geneeskd. 2006 Oct 7;150(40):2194-5. Ned Tijdschr Geneeskd. 2006. PMID: 17061430 Dutch.
• Bevacizumab beyond progression: does this make sense?
  Ellis LM, Haller DG. Ellis LM, et al. J Clin Oncol. 2008 Nov 20;26(33):5313-5. doi: 10.1200/JCO.2008.17.4540. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854567 No abstract available.
• Bevacizumab: one treatment for all the seasons?
  Gelibter AJ, Di Segni S, Zeuli M, Cognetti F. Gelibter AJ, et al. J Clin Oncol. 2008 Jan 20;26(3):511; author reply 511-2. doi: 10.1200/JCO.2007.15.0292. J Clin Oncol. 2008. PMID: 18202430 No abstract available.

Cited by

• Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy.
  Li Q, Geng S, Luo H, Wang W, Mo YQ, Luo Q, Wang L, Song GB, Sheng JP, Xu B. Li Q, et al. Signal Transduct Target Ther. 2024 Oct 7;9(1):266. doi: 10.1038/s41392-024-01953-7. Signal Transduct Target Ther. 2024. PMID: 39370455 Free PMC article. Review.
• Identification and Activity Study of an Impurity Band Observed in the nrSDS-PAGE of Aflibercept.
  Li M, Li W, Wang X, Wu G, Du J, Xu G, Duan M, Yu X, Cui C, Liu C, Fu Z, Yu C, Wang L. Li M, et al. Pharm Res. 2024 Oct;41(10):2031-2042. doi: 10.1007/s11095-024-03773-4. Epub 2024 Sep 25. Pharm Res. 2024. PMID: 39322793
• Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis.
  Zhou P, Zhang S, Li L, Zhang R, Guo G, Zhang Y, Wang R, Liu M, Wang Z, Zhao H, Yang G, Xie S, Ran J. Zhou P, et al. Theranostics. 2024 Aug 19;14(13):4983-5000. doi: 10.7150/thno.98467. eCollection 2024. Theranostics. 2024. PMID: 39267779 Free PMC article.
• Targeting the tumour vasculature: from vessel destruction to promotion.
  Guelfi S, Hodivala-Dilke K, Bergers G. Guelfi S, et al. Nat Rev Cancer. 2024 Oct;24(10):655-675. doi: 10.1038/s41568-024-00736-0. Epub 2024 Aug 29. Nat Rev Cancer. 2024. PMID: 39210063 Review.
• Pathophysiology in Brain Arteriovenous Malformations: Focus on Endothelial Dysfunctions and Endothelial-to-Mesenchymal Transition.
  Jeong JY, Bafor AE, Freeman BH, Chen PR, Park ES, Kim E. Jeong JY, et al. Biomedicines. 2024 Aug 7;12(8):1795. doi: 10.3390/biomedicines12081795. Biomedicines. 2024. PMID: 39200259 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information